Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41  by Burrer, Renaud et al.
www.elsevier.com/locate/yviroVirology 333 (20Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G
from infected patients capture HIV-1 via antibodies directed against the
principal immunodominant domain of gp41
Renaud Burrer1, Sandrine Haessig-Einius, Anne-Marie Aubertin, Christiane Moog*
EA3770, Institut de Virologie, Universite´ Louis Pasteur, 3 rue Kœberle´, 67000 Strasbourg, France
Received 18 November 2004; accepted 31 December 2004
Available online 29 January 2005Abstract
We analyzed the factors influencing the binding of polyclonal immunoglobulin (Ig)G from HIV-infected patients to primary isolates (PI)
in capture assays and a potential correlation between this binding and neutralization. The fixation of antibodies (Abs) to viral particles was
measured by quantifying the capture of 4 PI by purified IgG immobilized onto a plate or by analyzing the capture of IgG–virus complexes
formed in solution. We found that the capture of virus and the formation of immune complexes is mainly achieved by Abs directed against
the principal immunodominant domain (PID) of gp41. We have further compared the binding measured by these two methods and the
neutralizing activity of our polyclonal IgG and found no correlation. Thus, capture assays, including the immune complex capture assay
that is more representative of bphysiologicalQ conditions, cannot be used as surrogate method for the investigation of the neutralizing
activity of Abs.
D 2005 Elsevier Inc. All rights reserved.
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Despite the induction of an intense virus-specific anti-
body (Ab) response during HIV infection, neutralizing Abs
(Nabs) able to inhibit infection of a broad range of primary
isolates (PI) are only poorly detected in sera and plasma
from HIV infected individuals. It has been stipulated that the
difference between neutralizing and non-neutralizing Abs
could lie in their ability to bind mature oligomeric spike and
that high affinity and/or avidity for infectious particles may
be the hallmark of Nabs. The measure of Abs binding to the
oligomeric envelope has been proposed as a tool for the
investigation of the neutralizing activity of Abs, to evaluate
the immune responses induced by vaccination, for example.
Some groups have indeed described a correlation between0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Research Institute, La Jolla CA.the capacity of monoclonal Abs (MAbs) to bind env-
transfected (Schonning et al., 1999) or infected (Parren et al.,
1998; Sattentau and Moore, 1995) cells and to neutralize
viruses. Authors in favor of that spike binding/neutralization
correlation hypothesis have suggested that any antibody
able to bind the functional spike would neutralize irrespec-
tive of epitope specificity (Parren et al., 1998), or that even
Abs recognizing structures other than functional spikes at
the virus surface may participate to neutralization (Burton
et al., 2001; Klasse and Sattentau, 2002). Their proposals
are nonetheless controversial as reports from other groups
have shown that binding to particles (Nyambi et al., 2000b;
Poignard et al., 2003; Stamatatos et al., 1997) or to env-
expressing cells (Fouts et al., 1998) was not sufficient for
monoclonal Abs (MAbs) to neutralize the virus. In these
later studies, authors used virus capture assays and reported
efficient capture of viral particles by non-neutralizing Mabs.
Other found nonetheless the efficiency of capture of intact
virions by anti-V3 Mabs to be significantly correlated with
neutralizing activity (Gorny et al., 2004). In the only study05) 102–113
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Cavacini et al. reported that sera from infected patients only
weakly capture HIV-1 PIs (Cavacini et al., 1999). However,
these authors showed that those polyclonal IgG samples that
efficiently capture PIs all neutralize the viruses, although
33% of neutralizing samples did not bind viral particles at a
detectable level.
Whether these variations in the results obtained were due
to the experimental conditions used need to be further
defined. Virus capture assays (retention of the virus by
specific MAbs coated on a plate, followed by ELISA dosage
of the released viral antigen after lysis) were first designed
to detect cellular proteins associated to HIV-1 envelope
(Orentas and Hildreth, 1993). This type of test have since
frequently been used for this purpose (Bastiani et al., 1997;
Frank et al., 1996) or to study the binding of MAbs to HIV-1
glycoproteins at the virus surface (Gorny et al., 2004;
Nyambi et al., 1998, 2000a, 2000b, 2001; Poignard et al.,
2003). Poignard et al. (2003) have suggested that capture
assays are not appropriate to quantify epitope exposure on
gp120 at the surface of primary HIV-1 and proposed an
artifactual increase in the Ab capacity to bind viral particles
in conditions were IgG are immobilized on the plate.
Moreover, we suspected that the use of culture supernatant
as a source of virus particles (Cavacini et al., 1999; Nyambi
et al., 1998, 2000a, 2000b, 2001; York et al., 2001) or
pseudotyped virus (Poignard et al., 2003) may be another
possible weakness of the assay, as those preparations also
contain virus debris and shed gp120.Fig. 1. Neutralization and binding of HIV PI by purified IgG samples and monoclo
their ability to neutralize none, one or more than one PI. Neutralization is expressed
TCID50) for purified IgG samples, or as the minimal concentration (in Ag/ml) of M
of at least two independent experiments: -neutralizing titer b10 or IC90 N100 Ag/m
bars represent the mean and standard deviation of two or three independent expeTo take these weaknesses into account, we considered
capturing HIV-1 PIs by MAbs and polyclonal IgG samples
after purification of virions and elimination of the glyco-
proteins that are not presented in the context of virus
particles. We also developed a new assay where immune
complexes formed in solution were separated from the bulk
of unbound IgG before the capture step. A possible
correlation between binding of antibodies to virus under
these conditions and neutralization was investigated.Results
Absence of correlation between neutralization of PIs and
capture of purified virus particles by polyclonal IgG
Nineteen IgG samples from infected patients were
selected for displaying different neutralizing activities
against 4 PIs (Fig. 1a). Seven of them are devoid of any
detectable neutralizing activity (group 1), 6 neutralize a
single isolate (group 2) and 6 neutralize more than one PI
(group 3). Among these, 3 neutralize two isolates, 1
neutralizes three PIs and IgG samples 33 and 35 neutralize
the 4 PIs tested. As shown in a previous study, PI Bx08 is
relatively highly sensitive to neutralization, Bx17 and
11105C display an intermediate profile, and Kon is highly
resistant to neutralization (Burrer et al., 2001). MAb b12
and 2F5 were able to neutralize Bx08, Bx17 and 11105C
with various efficiencies, and MAb 2G12 neutralized onlynal antibodies. (a) IgG samples were divided in three groups on the basis of
as neutralizing titers (reciprocal of dilution that results in a 90% decrease of
Ab that induces the same loss of infectivity (IC90). Values represent mean
l MAb. (b) Ratio of p24 captured versus p24 added to the plate. Histogram
riments.
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not neutralized by any of the three MAbs at 100 Ag/ml.
We measured the capture of the 4 purified PIs by the
polyclonal IgG samples and found a linear relation between
the amount of purified virus incubated in the plate and the
virus retained by the IgGs (Fig. 2). However, as we use the
virus immediately after purification, exact concentration of
p24 was only known later on, after the binding experiment
was performed. So, to be able to compare the 4 primary
isolates, the captures were done using 3 two-fold dilutions
of each purified virus in duplicate wells and the virus
captured by IgG was expressed as the ratio between the
amount of p24 captured by Ig to the amount of p24 added in
the plate. All the 19 polyclonal IgG samples tested were able
to capture the 4 PIs, although with various efficiencies (Fig.
1b). For some samples as for example No. 8, capture (values
above mean negative control plus three standard deviations)
is only detected when high virus concentrations are added to
the ELISA plate.
It is noteworthy that no significant difference in the
average binding was observed between IgG groups, namely
the non-neutralizing IgG samples, the group 2 of IgG
samples that neutralized only Bx08 and the group 3 that
neutralized more than one PI. This absence of correspond-
ence between neutralization and binding was also verified
at the individual level. We found in particular the IgG
sample 8, that displays the highest neutralizing titer for
Bx08, to strikingly be the sample that captured that PI the
least (only slightly above background level), whereas mostFig. 2. Linear relationship between virus capture and virus incubated on the plate.
group is recorded for 3 two-fold dilutions of the 4 purified PI (Bx08, Bx17, 111IgG samples including non-neutralizing ones bound Bx08
efficiently. Moreover, as for the polyclonal-purified IgG
samples, there was no direct correlation between binding
and neutralization by the three MAbs included in this study.
Indeed, the capture by 2F5 is inefficient, and b12 captures
only poorly these four PI, although these two MAbs
neutralize 3 of them (Fig. 1b). On contrary, 2G12 only
neutralizes Bx08 at 100 Ag/ml but captures well Bx08 and
Bx17 (Figs. 1b and 2). Thus, whatever the virus consid-
ered, capture of virus by polyclonal or MAbs did not reflect
neutralization.
When comparing the capacity of each virus to be
captured by the polyclonal IgG, we noticed that virus
suspensions containing higher concentration of p24 were
required to reveal the capture of Kon or 11105C compared
to Bx08 and Bx17 (Figs. 1b and 2). The ratio of p24
captured compared to the amount of p24 added to the plate
was always higher for Bx08 (subtype B) and Bx17 (subtype
A) (Fig. 1b). Indeed, a linear relationship between the
capture of virus Bx08 and the capture of virus Bx17,
11105C or Kon (Fig. 3) was observed. The correlation of the
binding capacities of the IgG to these four viruses was
highly significant (Pearson correlation, P b 0.01) (Fig. 3).
These results suggest that the IgG could bind the same
motifs at the surface of virions, that is, either conserved
regions of the viral glycoproteins, or proteins of cellular
origin with quite similar efficiency for Bx08 and Bx17, but
with lower efficiency for virus 11105C, Kon being the less
easily captured.The amount of virus captured by mAb 2G12 or by 1 polyclonal IgG of each
05C and Kon). Values representative of 3 independent experiments.
Fig. 3. Binding of Bx08, Bx17, 11105C and Kon by IgG from infected
patients are correlated. (a) The ratio p24 captured versus p24 added to the
plate (103) from Fig. 1 have been reported on the x axis for Bx08, and
on the y axis for Bx17, 11105C and Kon. A linear correlation was
calculated. (b) The Pearson correlation coefficient was computed (r). They
are all statistically significant (P b 0.01).
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these four PIs was different according to the epitope
recognized. Binding of viruses to 2F5 is negligible. IgG1b12
binds with a similar low efficacy the 4 viruses. For 2G12, the
capture of Bx08 and Bx17 is more pronounced than for
11105C or Kon.Fig. 4. Capture of Bx08 and gp120-depleted viral particles by immobilized IgG
depleted, empty bars) or PBS (whole virus, black bars) and purified by gel-filtratio
of p24 recovered after capture of viral particles is determined. Results represent tCapture of viral particles by polyclonal IgG samples after
depletion of Ig directed against cellular antigens
The possibility that the binding of PIs by polyclonal IgG
samples could be mediated by Abs that target cellular
antigens was evaluated by comparing the capture of
untreated IgG samples to samples previously incubated
with PBMC in order to deplete cell-surface-binding IgG.
Capture of the virus by IgG samples previously incubated
on PBMC was not decreased compared to untreated control
IgG samples (data not shown), suggesting that the capture of
PIs by polyclonal IgG did not occur primarily through
cellular antigens incorporated into the virion membrane.
The capture of viral particles was not principally mediated
by Ab directed against gp120
To define if the capture of polyclonal IgG was mediated
by Abs that bind the surface subunit of the envelope glyco-
proteins, we measured the capture of the four PIs purified
after sCD4-induced gp120 shedding. Under these experi-
mental conditions, a 70% shedding of gp120 was obtained
whereas in the control virus without sCD4 treatment, gp120
was only detected in the peak containing the infectious virus
(data not shown and Burrer et al., 2003). Virus capture assays
were performed in parallel with control and gp120-depleted
viruses. As expected, the shedding of gp120 resulted in a
decrease of the capture of Bx08 by the anti-gp120 MAb
2G12, while no significant variations were observed for the
anti-gp41 MAb 2F5 or for MAbs to cellular CD2, CD5,
CD11a, or CD48 (Fig. 4). On contrary, the capture of the
viral particles was significantly increased after shedding of
gp120 for all the purified IgG samples, the relative increase
being very similar for the three neutralization groups. Indeed,
for Bx08, the shedding of the gp120 resulted in augmenta-
tion of 136% F 26% for the non-neutralizing IgG samples. Viral particles that were incubated with either 50 Ag/ml sCD4 (gp-120
n were captured by IgG from infected patients and MAbs. The concentration
he mean and standard deviations of two independent experiments.
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Bx08 only (n = 4), and 123% F 34% for the cross-
neutralizing IgG samples (n = 7). Similar increased binding
of gp120 depleted virus was observed for the three other PI
used in this study (data not show and Fig. 6). These
augmentations suggest that the partial shedding of gp120
facilitates the recognition of epitopes on virus particles and/
or that the increased binding is due to antibodies directed
preferentially against gp41 which is now more accessible.
In order to assess the first hypothesis, we increased the
dissociation of gp120 by adding bathophenanthroline to
sCD4. As previously published by Demaria et al. (1995), we
were able to dissociate 95% of gp120 under these
conditions, but these gp120-depleted particles were also
captured more efficiently. We detect an average augmenta-
tion of 138% F 26% of the binding of Bx08 to the
polyclonal IgG samples (n = 5) that is comparable to the
augmentation detected with virus treated with CD4 only.
The second hypothesis of a preferential capture of viruses
via Abs directed to gp41 epitopes was examined. As gp41
contains the principal immunodominant domain (PID), we
analyzed whether Abs directed to this domain could
participate to virus capture. By adding in the capture
experiments, peptide with the PID sequence in competition
with virus, a 50 to 70% decrease in Bx08 capture by
polyclonal IgG samples 14 or 33 was evidenced at
concentrations of PID peptide ranging from 1 to 200 Ag/
ml (Fig. 5). Similar loss of capture in presence of PID
peptide was repeatedly detected with 6 additional polyclonal
Abs (sample 4, 8, 12, 18, 20, 39) whether they were
neutralizing or not, and for virus Bx08 that have loss 70% ofFig. 5. Competition of Bx08 capture with PID peptide, V3 peptide or
gp160DPID. Results are expressed as the percentage of virus captured by
polyclonal IgG sample 14 and 33 in presence of negative control peptide
(empty bars), 20 Ag/ml gp160DPID (streaked bars), various concentrations
of V3 peptide (hatched bars), various concentrations of PID peptide (dotted
bars) or combination of 20 Ag/ml gp160DPID with 50 Ag/ml PID (black
bar) compared to the capture in absence of peptides or gp. Mean and
standard deviations from duplicates.gp120 after sCD4 treatment (data not shown). These
diminutions were also detected for capture of Bx17 or
Kon viruses (treated or not with sCD4 to decrease gp120
concentration) in presence of PID peptide (Fig. 6). When V3
peptide (at 10 or 100 Ag/ml) or recombinant Bx08
gp160DPID (at 20 Ag/ml) was added in competition, the
decrease in virus capture by polyclonal Abs was much less
pronounced (10 to 35% depending of the virus analyzed)
than with PID peptide (Figs. 5 and 6). We, however, found
85% and 97% decrease capture of virus Bx17 and Kon,
respectively by 2G12 in presence of gp160DPID demon-
strating that this concentration of recombinant glycoprotein
efficiently interferes with the capture of the virus by
this MAb directed against an epitope accessible on gp120
(Fig. 6). Moreover, by combining the PID peptide at 50 Ag/
ml with gp160DPID at 20 Ag/ml, the inhibition of virus
capture was slightly improved compared to PID peptide
alone (Figs. 5 and 6) revealing an additive effect, expected if
antibodies directed against both structures were responsible
for the capture.
These results strongly suggest that the capture of the PIs
by these polyclonal Abs is predominantly achieved by Abs
directed against the PID, and that the increased capture of
virus particles after gp120 dissociation is due to an
augmentation of gp41 accessibility after shedding of gp120.
Antibodies directed against PID peptide, V3 peptide and
gp160DPID
To further verify this hypothesis, we measured the
relative amount of antibodies able to bind the PID peptide
in our different polyclonal samples. It was shown to be
highly correlated (P b 0.001) with the ratio of p24 captured
compared to total amount of p24 added for the four virus
tested (Fig. 7). On contrary, the correlation between the
relative amount of antibodies able to bind gp160DPID and
the virus captured is much less pronounced except for virus
Kon (Fig. 7) and no correlation was found between the
relative amount of antibodies able to bind V3 peptide and
the virus captured. These results further suggest that the
capture observed with these polyclonal antibodies can be
mainly attributed to antibodies directed against the PID.
Capture of purified IgG-viral particles complexes
To assess the possibility that the coating of Abs on the
plate may alter their ability to bind to viral particles, we
have developed experimental conditions where virus/Ab
complexes are formed in solution and separated from the
bulk of unbound IgG by gel-filtration before being captured
on a plate coated with anti-Fc MAbs. The binding to the PIs
of 7 selected purified IgG samples has been analyzed by this
method. Results of experiments performed with PI Bx08 are
presented in Fig. 8. Capture values that exceeded 60 pg p24
(highest negative control value + two standard deviations)
were considered positive. Bx08 was efficiently captured by
Fig. 6. Competition of Bx17 or Kon capture with PID peptide or gp160DPID. Capture by the non-neutralizing polyclonal IgG sample 3, neutralizing IgG
samples 33 and 4 or mAb 2G12 either mock-treated (empty bars) or treated in presence of 20 Ag/ml gp160DPID (dotted bars), of 50 Ag/ml PID peptide
(hatched bars) or the combination of 20 Ag/ml gp160DPID with 50 Ag/ml PID (black bars). The viruses Bx17 and Kon are either untreated or incubated with
sCD4 to induce 70% gp120 shedding before purification. Capture of Kon in presence of PID peptide and PID peptide + gp160DPID have not been done with
mAb 2G12.
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extent (Fig. 8). Binding of that isolate was detected up to the
1/500 dilution in samples 8 and 12, and up to the 1/5000 for
the 4 other IgG samples tested. As for virus capture assay,Fig. 7. Correlation between the ratio p24 captured versus p24 added to the plate an
V3 peptide. The Pearson correlation coefficient was computed (r). For statistical an
than 10.the amount of virus engaged in immune complexes formed
in solution with IgG8 and captured is low compared to the
other IgG samples tested. Thus, results obtained with
immune complex capture assay where free IgG interactd the relative amount of Ab directed either to PID peptide, gp160DPID or to
alysis, we used exact (permutation) tests as the number of subjects was less
Fig. 9. Competition of immune complex formation with PID, V3 peptide or
Fig. 8. Binding of purified IgG–Bx08 complexes. After incubation of serial dilution of IgG samples with Bx08, IgG–virions complexes were separated from the
bulk of antibodies by gel-filtration and captured onto a plate. Data represent the mean of p24 captured in at least two independent experiments for each IgG
dilution. Full lines indicate neutralizing and dashed lines non-neutralizing IgG samples (as determined by the neutralization assay, Fig. 1a).
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IgG sample 8 binding to Bx08 primary isolate. Again, no
correlation could be found between the amount of immune
complexes captured and neutralization as, for example, the
immune complexes formed with the non-neutralizing IgG 3
are captured as efficiently as immune complexes formed
with IgG 33 that neutralize efficiently Bx08. Similar
discrepancies between capture of immune complexes and
neutralization was also seen for Bx17 and virus Kon (data
not shown) demonstrating that this analysis of the binding of
antibodies to virus using this immune complexes capture
assay will also not help to predict the neutralizing function
of the Abs.
To further analyze the contribution of Abs directed to the
various epitopes exposed on native particles in the
formation of immune complexes, the polyclonal IgG
samples were incubated with the viruses in competition
with PID peptide, V3 peptide or gp160DPID. Addition of
recombinant gp160DPID at 48 Ag/ml decreases immune
complex capture by 45% (Fig. 9). A similar 45% decrease of
immune complex capture was detected in competition
experiments with PID peptide at 160 Ag/ml (Fig. 9).
However, Bx08 V3 peptide at the same concentration was
not able to decrease immune complex capture (Fig. 9). The
inhibition of immune complex capture by peptide or rgp is
only evidenced with the highest dilutions of IgG (1/500)
tested (data not shown). Thus, when Abs are in solution,
various part of gp160 are involved in the binding of Abs to
native particles, although Abs directed against PID largely
contribute to this binding.gp160DPID. Results are expressed as the percentage of the capture of
immune complex formed after 1 h incubation of virus Bx08 with polyclonal
IgG sample 3 or 33 (at 1/500 dilution) and either negative control peptide
(empty bars), various concentration of gp160DPID (dotted bars), 160 Ag/ml
V3 peptide (hatched bars) or 160 Ag/ml PID peptide (black bars) compared
to the capture of immune complexes formed in absence of peptides or gp.
Mean values from duplicates.Discussion
In this study, we have demonstrated that all the
polyclonal IgG samples purified from HIV infected indi-vidual tested were able to bind the 4 PIs although with
various efficiencies and that the capacity of these IgG to
capture primary isolates was not correlated to their
neutralizing activity. These results are different from those
previously reported showing that neutralization of PIs was
positively associated to high levels of Ab binding to virus,
although they also found that some neutralizing polyclonal
sera did not efficiently capture PIs (Cavacini et al., 1999).
Contrary to Cavacini et al., we purified the virus and IgG to
be used in the capture assay. However, as we found similar
amount of virus captured using non-purified virus (data not
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account for the higher capture efficiency found in our study.
The virus capture test was initially designed to quantify
the binding of MAbs to viral particles. When used with
polyclonal samples immobilized on the plate, it will rather
measure the ratio of particle-binding versus total IgG rather
than the absolute concentration of viral particles-binding
antibodies. Moreover, the accessibility of the paratopes of
immobilized Ab may be restricted compared to free Abs
(Poignard et al., 2003). We have thus developed an IgG–
virion complex capture assay to analyze more physiological
virus–IgG interactions. Using this latter assay where IgG
and viruses were incubated free in solution before purifica-
tion of immune complexes, we again did not find any
correlation between binding and the neutralizing activity of
the IgG.
We showed that virus capture by polyclonal antibodies
was not decreased in presence of V3 peptide even at high
concentration (100 Ag/ml). This result is surprising because
the V3 loop has been described to be easily accessible on
HIV native particles (Gorny et al., 2004) and in particular on
Bx08 primary isolate (Nyambi et al., 2000b) contrary to
what was previously thought (Bou-Habib et al., 1994). We
have found that the efficiency of the capture was directly
correlated with the relative amount of Ab directed to the PID
epitope and can be decreased by up to 85% in presence of
PID peptide. Previous studies have shown that, among
various mAb/virus combinations, mAbs 246-D and 240-D
directed to epitopes located at the apex of the hydophophilic
PID bound strongly to all or most of the isolate tested using
comparable capture conditions (Nyambi et al., 2000b). The
authors conclude from their study that the PID of gp41 is
well exposed on the surface of intact, infectious virions and
that the strong binding of their mAbs is not due to gp120
shedding (Nyambi et al., 2000b). Moreover, we have shown
that addition of the whole recombinant gp160 of Bx08
deleted by the PID peptide (gp160DPID) in competition
with virus had only a low inhibitory effect on binding of
polyclonal Abs to virus. This concentration of gp160DPID
is however sufficient to allow a drastic (85%) decrease of
virus capture by the 2G12 MAb. These results imply that the
concentration of gp160DPID added in the capture experi-
ment should have been sufficient to decrease the capture of
virus by polyclonal IgG if binding was achieved by Abs
directed to monomeric gp160 epitopes outside PID, and
further strengthen our conclusion that Abs directed to PID
peptides are mainly responsible for virus capture.
The increase of virus capture by polyclonal Abs after
gp120 dissociation is also in favor of predominant capture
of virus by Abs directed to gp41. Similar increase virus
capture in presence of sCD4 was previously noticed with
V3Mabs (Mbah et al., 2001). However, in that case, sCD4
used at 20-fold lower concentration was expected to induce
modification of gp120 conformation rather than shedding of
gp120. As more than 95% gp120 shedding was observed in
presence of bathophenanthroline, increased accessibility ofgp120 to Abs may not account for the increase in capture
observed here.
The high prevalence of virus capture by Abs directed
against the PID peptide was unexpected. Abs of this
specificity have been shown to be efficiently induced after
infection as well as Abs directed against gp120 (Parekh
et al., 2001). Although the concentrations of Abs directed
against each epitope in our polyclonal IgG samples have not
been assessed, we used 40-fold lower dilution of polyclonal
IgG to analyze the relative amount of Abs binding to
gp160DPID compared to PID and 4-fold lower concen-
tration of polyclonal IgG to analyze the relative amount of
Abs directed to V3, indicating the presence of high level of
Abs directed to epitopes outside the PID epitopes. Indeed,
antibodies to discontinuous or conformational sensitive epi-
topes on the gp120 have been shown to be highly prevalent
in sera from HIV-infected individuals (Moore and Ho,
1993), most of them being directed against the CD4 binding
site and the V3 loop (Moore et al., 1994). As various
epitopes on gp120 (especially the V3 loop) have been
shown to be accessible on the surface of PIs using capture
experiment with similar experimental conditions, one may
suggest that the epitopes on gp120 are less accessible than
PID epitopes favoring capture by antibodies directed against
PID when Abs are in competition for virus capture in the
case of polyclonal samples. Another explanation could be
that the antibodies directed to gp120 present in our poly-
clonal samples are too specific or with too low affinity to
capture heterologous virus. Indeed, in the capture test
performed with IgG that were immobilized, high avidity
for virus particles may be necessary. Poignard et al. (2003)
have on contrary proposed that the virus capture conditions
will advantage antibodies with low affinity. They have
shown that the Mab IgG1b12 was able to capture a IgG1b12
neutralization escape virus and have proposed that the
different requirement for virus capture and neutralization is
likely to be related to low affinity of Abs sufficient to
capture virus presumably through multivalent interactions of
viral envelope with immobilized Ab on a surface but
insufficient to neutralize the virus.
The constraints due to immobilization of Ab to the plate
cannot be taken into account in our second assay where
immune complexes are formed in solution and thereafter
captured via an anti-human IgG MAb. In this assay,
however, immune complexes are obtained by gel filtration
after a 2-h purification process time during which antibodies
with low affinity may dissociate from virions with no re-
association occurring after separation of free antibodies.
Under these conditions, a decrease of the amount of immune
complex captured was detected when the complex was
formed in presence of PID peptide, demonstrating that the
Abs directed to PID peptide also interfered with the binding
to virus when Ab are in solution. Addition of V3 peptide has
no effect on immune complex formation and capture.
However, a decrease was also observed when gp160DPID
were added in competition with virus for immune complex
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decreased capture of immune complex observed when
formed with PID or gp160DPID is however less pronounced
than that observed for virus capture in presence of PID
peptide. Indeed, in the virus capture experiment, only few
Abs are retained on the plate and lower concentrations of
PID peptides may thus be sufficient to inhibit the capture of
the virus compared to the experiment where Ab, virus and
peptides or gp160DPID are in solution and can interfere
with each other before immune complex purification. More-
over, for the immune complex capture assay, we have used
serial dilutions of Ab. At lower IgG concentrations, lower
number of antibodies should be bound per virus in the
immune complex. We could speculate that at limiting
polyclonal Ab dilution, the binding of one antibody mole-
cule is able to allow immune complex capture. This would
signify that, at low IgG concentrations and for the PID
peptide concentration used, a large fraction of the Abs
retained in the immune complex capture experiments are
directed against PID epitope. At higher concentrations of
IgG, the number of Ab bound to virus particles may increase
and higher PID peptide concentration may thus be needed to
inhibit binding of multiple IgG to the same virus particle.
According to Chertova et al. (2002), the number of envelope
spikes per PI may be much lower (7 to 14 trimers) than
previously thought, and they found gp120 and gp41 to be
present in similar molecular ratio on primary isolates which
argue against shedding of gp120. This would indicate that
the number of Ig bound to virus to form the immune
complexes do not exceed 14 if only one antibody binds per
trimer. Unfortunately, we were unable to estimate the num-
ber of Ab bound to virus particles by performing an IgG
ELISA as previously described (Burrer et al., 2001) on the
immune complex capture assay, as the amounts of IgG were
below detection (data not shown).
We have shown that virus capture and to a lesser extend,
immune complex formation is mainly attributed to Abs
directed against PID peptides. When the neutralizing
activity of polyclonal samples Nos. 4, 33, and 44 was
assessed in presence of 100 Ag/ml PID peptide, concen-
tration that strongly decreases virus capture and immune
complex formation, we could not detect a diminution of the
neutralization titer, suggesting that in these samples, the Abs
directed against PID are not neutralizing. Indeed, Abs
directed against PID have not been shown to display
neutralizing activity (Xu et al., 1991) but have been reported
to induce enhancement (Richardson et al., 1997; Robinson
et al., 1990). We have previously shown that the immune
complexes formed between virus and non-neutralizing Abs
were 100% infectious (Burrer et al., 2003). As in this study,
we found that this binding was mainly achieved by Abs
directed to PID, this suggests that the binding of Abs to PID
at the surface of HIV particle does not modify infectivity.
Contrary to immune complexes formed with non-neutraliz-
ing IgG samples, the immune complex formed with the
neutralizing polyclonal IgG samples used in the presentstudy (i.e., IgG sample 8, 33, 39, 44) have lost their
infectivity (Burrer et al., 2003) demonstrating that the
neutralizing Abs present in these polyclonal samples also
efficiently bind to free virus particles.
Concerning the mAbs analyzed in our study, the broadly
neutralizing antibody 2F5, that recognizes an epitope on
gp41 is not able to bind efficiently primary isolate as
previously published (Nyambi et al., 2000b). The neutraliz-
ing Ab IgG1b12 only slightly binds to PI Bx08 compared to
mAb 2G12 (Fig. 1b). These results are similar to the results
published by other using comparable IgG1b12/Bx08 capture
conditions (Nyambi et al., 2000b), or analyzing binding of
IgG1b12 and 2G12 to Bx08 infected PBMC (Gorse et al.,
2004). In order to explain the discrepancy between binding
of IgG1b12 to primary isolates in the virus capture assay
and neutralization, Poignard et al. (2003) have proposed that
this Ab binds the functional spikes on virus particles,
whereas non-neutralizing antibodies bind only to defective
spikes. The capture assays used in this study will not
discriminate between binding to functional or defective
spike, they will also not distinguish between capture of
infectious versus non-infectious virus. The results presented
in this study however clearly demonstrate that binding of Ab
to the primary isolates analyzed either by virus capture or
the more bphysiologicalQ immune complex capture assays
cannot be used as surrogate assays for the investigation of
the neutralizing activity of Abs.Material and methods
Production of virus stocks and purification of virus particles
PIs Bx08, Bx17 (subtype B and A, respectively, both R5
and provided by Pr. H. Fleury), 11105C (subtype A, R5,
provided by Pr. F. Barre-Sinoussi) and Kon (subtype A/G,
X4, provided by Pr. F. Barin) were propagated once or
twice, exclusively on freshly isolated Peripheral Blood
Mononuclear Cells (PBMC, pool of three donors, purified
by Ficoll gradient and phytohemagglutinin A-stimulated for
3 days) as previously described (Moog et al., 1997;
Spenlehauer et al., 2001). For some capture experiments,
virus stocks were concentrated 80-fold through a 100-kDa
cut-off polyethersulfone filter (Centricon 80 Plus Biomax
Filter, Millipore, Molsheim, France), according to the
manufacturer’s instructions.
To remove free p24 and gp120 that could interfere during
capture experiments, viruses were purified by a gel-filtration
method adapted from Moore et al. (1990). Briefly, 5 ml viral
culture supernatant was loaded on Sephacryl S-1000
Superfine (Amersham) (35 ml gel bed for a 19 cm column
length) and eluted by phosphate-buffered saline (PBS).
Titration of the infectious virus and dosage of p24 and
gp120 in the different fractions were performed as
previously described (Burrer et al., 2003). The fractions
containing the infectious virus were pooled to obtain 7.5 ml
R. Burrer et al. / Virology 333 (2005) 102–113 111purified virus (Burrer et al., 2003). This purified fraction
contains all the gp120 and 15 to 30% of the p24 of the non-
purified virus stock, as determined by ELISA (data not
shown).
IgG from serum and plasma samples were routinely
purified by Protein A affinity chromatography, as previously
described (Burrer et al., 2001, 2003; Spenlehauer et al.,
2001), to ascertain the origin of the inhibitory activity
present in plasma or serum. The dilution of IgG samples
used for both neutralization and capture assays refers to
crude serum/plasma. An IgG sample purified from one
seronegative donor as well as a pool of IgG from three
seronegative individuals sera were used as HIV-1 negative
controls. MAbs 2F5 and 2G12 were given by Pr. H.
Katinger and provided by the EU Programme EVA/MRC
Centralized Facility for AIDS Reagents, NIBSC, UK (Grant
Number QLK2-CT-1999-00609 and GP828102). MAb b12
(IgG1b12) was given by Pr. D. Burton and Dr. P. Parren.
Neutralization of HIV-1 PIs by purified IgG from infected
patients
Our standard neutralization assay (Burrer et al., 2001,
2003) measures the variations of the viral titer in presence of
Ab, the neutralization titer being defined as the serum
dilution resulting in a 90% decrease of viral TCID50. The
analysis of PIs neutralization by IgG purified from serum
and plasma samples collected from HIV-infected patients
was previously reported (Burrer et al., 2001). On the basis
of these results, 19 IgG samples with various neutralizing
profiles that were obtained from patients with a mean
duration of infection of 8.5 years (range 3–17) and a mean
CD4 counts of 770/mm3 (range 215–1800/mm3) have been
selected.
Capture of PIs by immobilized IgG
For the virus capture assay, 96-well plates (Maxisorp,
Nunc) were coated overnight at 4 8C with 100 Al per well of
anti-human IgG Fc (AU004, the Binding Site, Birmingham,
UK), diluted 1/1000 in 50 mM bicarbonate buffer (pH 9.6).
After one wash (200 Al of PBS 0.05% Tween-20), the plate
was saturated 1.5 h at 37 8C with 200 Al of PBS 5%
dehydrated low fat milk. The plate was washed three times
and duplicate 100 Al samples of purified IgG from infected
patients diluted 1/100 in PBS 5% dehydrated milk
(containing 70 to 140 Ag/ml proteins) were added to the
wells. After 1 h at 37 8C, the plates were washed (three
times 200 Al of PBS 10% FCS each), and incubated 2 h at
37 8C with 100 Al of 3 two-fold dilutions of gel-purified
virus. The virus purification was performed freshly for
every experiment to minimize viral particles degradation.
Extensive washings were done (5 washings with 200 Al of
PBS 10% FCS each) and bound viral particles were
disrupted by addition of 150 Al of NP40 solution. For each
IgG sample, the amount of virus captured was determined asthe mean of p24 quantity in duplicate wells, measured by
ELISA (Innotest, Innogenetics, Ghent, Belgium). OD values
of p24 measured after virus lysis were converted to pg/ml
using the serially diluted standard, they were considered
positive when higher than the mean negative control plus
three standard deviations. In the experiments, where the
capture of different virus strains was compared, capture
values are expressed as the ratio between the amount of p24
captured and the amount of p24 added on the plate.
Capture of viral particles after depletion of cellular antigens
specific IgG in polyclonal IgG samples
The possibility that the binding of PIs by polyclonal IgG
samples could be mediated by Abs that target cellular
antigens was evaluated. In order to deplete cellular receptor-
binding IgG, IgG samples (diluted 1/10 to contain between
0.7 and 1.4 mg/ml proteins) were incubated for 2 h at 37 8C
with 500 Al of RPMI containing 5.106 PBMC (pooled as for
virus production). Cells were removed by centrifugation and
cellular antigens-depleted IgG samples were compared to
mock-treated controls in the capture assay.
Capture of viral particles after gp120 dissociation
To estimate the percentage of capture of the PI mediated
by Abs that bind the surface subunit of the envelope
glycoproteins, we measured the capture of Bx08 after sCD4-
mediated gp120 shedding. Briefly, viral culture supernatant
was incubated 1 h at 37 8C with 50 Ag/ml sCD4, or with
PBS for control, and viral particles were purified by gel-
filtration as previously described (Burrer et al., 2003). The
capture of control and gp120-depleted purified viral
particles was immediately compared as described above,
while p24 and gp120 concentrations were determined later
on in frozen aliquots of the samples, to make sure that
similar concentrations of viral particles were present and to
assess the level of shedding (Burrer et al., 2003).
Capture of purified IgG-viral particles complexes
In this assay, the 96-well plate was coated with anti-
human IgG and saturated in the same way as for viral
particles capture test except that after removal of the milk
solution, it was washed once with 200 Al of PBS 10% FCS.
Virions were extemporaneously purified by gel-filtration
(Burrer et al., 2003) and 500 Al aliquots of the purified virus
(150 to 300 ng/ml p24) were incubated 1 h at 37 8C with
500 Al of serial dilutions of purified IgG in PBS. For each
IgG dilution, viral particles were then separated from
unbound Abs by performing gel-filtration chromatographies
in parallel (as for virus purification). Duplicate 100 Al
aliquots of the gel-filtration fraction containing the purified
immune complexes were incubated on the anti-human IgG-
coated plate. After 1 h at 37 8C, the plate was washed and
the virus was lysed and the p24 quantified as for the virus
R. Burrer et al. / Virology 333 (2005) 102–113112capture test. The virus elution profile was monitored by
ELISA p24 antigen detection and the concentration of p24
captured in the peak fraction was used to compare the
capture of purified immune complexes formed with various
IgG samples.
Competition of virus capture with V3 peptide, PID peptide,
or gp160DPID
To evaluate capture of virus particles or immune
complexes via specific domains of the envelope proteins,
we incubated peptides or recombinant gp160DPID in
competition with virus/Ab binding. A 24 mer (593–616)
peptide corresponding to the principal immunodominant
domain (PID) was obtained through the NIBSC, centralized
Facility for AIDS Reagents supported by EU program EVA
Contract (QLK2-CT-1999-00609), and the UK Medical
Research Council. A 21-mer peptide corresponding to the
consensus sequence of the Bx08 V3 loop (Spenlehauer et
al., 1998) 14-mer (524–537) was used as well as a negative
peptide control, a 16-mer 421–436 peptides which corre-
spond to regions of gp160 that were poorly recognized by
Abs (data not shown). The recombinant gp160DPID HIV
(B) Bx08/LAI-DID, deleted in the PID sequence, was
kindly provided by R. El Habib, Aventis Pasteur. For virus
capture competition, 25 Al of peptides at various concen-
trations (ranging from 1 to 200 Ag/ml) or gp160DPID at 20
Ag/ml were incubated in the polyclonal IgG coated plate
for 1 h prior addition of the purified virus. For competition
of immune complex formation, 250 Al of PID peptide (at
160 Ag/ml), of V3 peptide (at 640 or 160 Ag/ml), of
negative control peptide (at 640 or 160 Ag/ml) or gp160 (at
48 or 10 Ag/ml) was added together with 250 Al IgG at
various dilutions and 500 Al virus (150 to 300 ng/ml p24)
for 1 h before purification of the immune complex by gel
filtration.
Binding of antibodies to PID, V3 peptide or gp160 DPID
The relative amount of Abs able to bind the PID, V3
peptide or gp160 DPID was determined by ELISA. Briefly,
100 Al of V3 or PID peptide (at 10 Ag/ml) or of gp160DPID
(at 0.5 Ag/ml) diluted in 50 mM bicarbonate buffer (pH 9.6)
was coated onto a 96-well plate (Maxisorp, Nunc) overnight
at 4 8C. After one wash (200 Al of PBS 0.05% Tween-20),
the plate was saturated 1.5 h at 37 8C with 200 Al of PBS
5% dehydrated low fat milk. The plate was washed three
times, and duplicate 100 Al samples of purified IgG from
infected patients were added, diluted at 1/100 and serially
two-fold diluted in PBS 5% dehydrated milk. After 1 h at
37 8C, the plate was washed (three times 200 Al of PBS 10%
FCS each), and 100 Al per well of anti-human Ig polyclonal
coupled to horseradish peroxidase (Southern Biotechnology
Associated, Birmingham, Ala), diluted 1/5000 in PBS 5%
dehydrated milk was incubated for 1 h at 37 8C before
addition of the substrate (TMB, Pharmingen). Dilution ofIgG samples allowing OD readout values lower than 1.5
(dilution of IgG samples of 1/400 for binding to PID
peptide, 1/1 600 for binding to V3 peptide and 1/16 000 for
binding to gp160DPID) were used.
Statistical analysis
Pearson correlation coefficient was computed to deter-
mine if there was a correlation between the capture of the
different viruses tested. For the analysis, the correlation
between capture and the amount of Abs was directed against
the PID peptide, V3 peptide or gp160DPID, we used the
exact (permutation) tests as the number of subjects was less
than 10. Computations were run on R.Aknowledgments
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